FindTrial
Sign In

A cohort study of Wubiefanchun oral liquid in the treatment of premature ovarian insufficiency

Two-way cohort study on hormone-like effects of Wubiefanchun oral liquid in the treatment of premature ovarian insufficiency based on propensity score

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2200006411
Enrollment
Unknown
Registered
2022-08-01
Start date
2022-07-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature ovarian insufficiency

Interventions

exposure group:Wubiefanchun oral liquid
non-exposure group:non-Wubiefanchun oral liquid

Sponsors

Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of POI TCM and Western Medicine

Exclusion criteria

Exclusion criteria: 1. Bilateral or unilateral oophorectomy 2. Combined with severe primary diseases such as acute infectious diseases, cardiovascular, renal, liver and hematopoietic systems. 3. Mental patients and or due to intellectual and behavioral disorders. 4. Allergic constitution or allergic to multiple drugs.

Design outcomes

Primary

MeasureTime frame
FSH;—

Countries

China

Contacts

Public ContactYU QIAN

Jiangsu Province Hospital of Chinese Medicine

yuqian227@njucm.edu.cn13645168827

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026